WO1995025518A1 - Aqueous solution of levocabastine for ophthalmic use - Google Patents
Aqueous solution of levocabastine for ophthalmic use Download PDFInfo
- Publication number
- WO1995025518A1 WO1995025518A1 PCT/IB1995/000143 IB9500143W WO9525518A1 WO 1995025518 A1 WO1995025518 A1 WO 1995025518A1 IB 9500143 W IB9500143 W IB 9500143W WO 9525518 A1 WO9525518 A1 WO 9525518A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ophthalmic solution
- aqueous ophthalmic
- weight
- levocabastine
- agent
- Prior art date
Links
- 229960001120 levocabastine Drugs 0.000 title claims description 34
- ZCGOMHNNNFPNMX-KYTRFIICSA-N levocabastine Chemical compound C1([C@@]2(C(O)=O)CCN(C[C@H]2C)[C@@H]2CC[C@@](CC2)(C#N)C=2C=CC(F)=CC=2)=CC=CC=C1 ZCGOMHNNNFPNMX-KYTRFIICSA-N 0.000 title claims description 34
- 239000007864 aqueous solution Substances 0.000 title abstract description 6
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims abstract description 14
- 239000002904 solvent Substances 0.000 claims abstract description 11
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims abstract description 3
- 208000002205 allergic conjunctivitis Diseases 0.000 claims abstract description 3
- 208000024998 atopic conjunctivitis Diseases 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims description 32
- 239000002997 ophthalmic solution Substances 0.000 claims description 27
- 229940054534 ophthalmic solution Drugs 0.000 claims description 26
- 238000009472 formulation Methods 0.000 claims description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 22
- 206010027654 Allergic conditions Diseases 0.000 claims description 13
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 12
- 239000004327 boric acid Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- -1 alkali metal acetates Chemical class 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 239000011780 sodium chloride Substances 0.000 claims description 11
- 239000000872 buffer Substances 0.000 claims description 9
- 229940124274 edetate disodium Drugs 0.000 claims description 8
- 239000003755 preservative agent Substances 0.000 claims description 7
- 239000003381 stabilizer Substances 0.000 claims description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- 229920000858 Cyclodextrin Polymers 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 230000002335 preservative effect Effects 0.000 claims description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 claims description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 4
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 claims description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 4
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 claims description 4
- 239000012929 tonicity agent Substances 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- 235000010323 ascorbic acid Nutrition 0.000 claims description 3
- 239000011668 ascorbic acid Substances 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 239000001923 methylcellulose Substances 0.000 claims description 3
- 235000010981 methylcellulose Nutrition 0.000 claims description 3
- RHEJCPIREFCJNF-UHFFFAOYSA-M 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-3-(2-phenylethyl)imidazol-1-ium;chloride Chemical compound [Cl-].ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)C[N+]1=CN(CCC=2C=CC=CC=2)C=C1 RHEJCPIREFCJNF-UHFFFAOYSA-M 0.000 claims description 2
- 239000004255 Butylated hydroxyanisole Substances 0.000 claims description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 229910001508 alkali metal halide Inorganic materials 0.000 claims description 2
- 150000001340 alkali metals Chemical class 0.000 claims description 2
- 229910001615 alkaline earth metal halide Inorganic materials 0.000 claims description 2
- 229960005070 ascorbic acid Drugs 0.000 claims description 2
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims description 2
- 229940043253 butylated hydroxyanisole Drugs 0.000 claims description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 2
- 239000001110 calcium chloride Substances 0.000 claims description 2
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 2
- 239000004202 carbamide Substances 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 229960004926 chlorobutanol Drugs 0.000 claims description 2
- 239000008121 dextrose Substances 0.000 claims description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims description 2
- 150000008040 ionic compounds Chemical group 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 2
- 229960002216 methylparaben Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 229940067107 phenylethyl alcohol Drugs 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 229940068984 polyvinyl alcohol Drugs 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 2
- 229960003415 propylparaben Drugs 0.000 claims description 2
- 229950003422 sepazonium chloride Drugs 0.000 claims description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 2
- 229940001584 sodium metabisulfite Drugs 0.000 claims description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 2
- 235000010199 sorbic acid Nutrition 0.000 claims description 2
- 239000004334 sorbic acid Substances 0.000 claims description 2
- 229940075582 sorbic acid Drugs 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims description 2
- 229960004906 thiomersal Drugs 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical group [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims 2
- 229940097362 cyclodextrins Drugs 0.000 claims 2
- 235000021317 phosphate Nutrition 0.000 claims 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 claims 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 1
- 229960004308 acetylcysteine Drugs 0.000 claims 1
- 150000001642 boronic acid derivatives Chemical class 0.000 claims 1
- 150000001860 citric acid derivatives Chemical class 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 229950008882 polysorbate Drugs 0.000 claims 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims 1
- 239000000243 solution Substances 0.000 abstract description 23
- PIZLBWGMERQCOC-UHFFFAOYSA-N dibenzyl carbonate Chemical compound C=1C=CC=CC=1COC(=O)OCC1=CC=CC=C1 PIZLBWGMERQCOC-UHFFFAOYSA-N 0.000 abstract description 4
- 229960001828 levocabastine hydrochloride Drugs 0.000 abstract description 4
- 239000000739 antihistaminic agent Substances 0.000 abstract description 2
- 230000002209 hydrophobic effect Effects 0.000 abstract description 2
- 230000003389 potentiating effect Effects 0.000 abstract description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 abstract 1
- 230000001387 anti-histamine Effects 0.000 abstract 1
- 239000000725 suspension Substances 0.000 description 19
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 229960001340 histamine Drugs 0.000 description 5
- 210000001742 aqueous humor Anatomy 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 3
- 206010010726 Conjunctival oedema Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 3
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- 239000001116 FEMA 4028 Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- OICFWWJHIMKBCD-VALQNVSPSA-N Livostin (TN) Chemical compound Cl.C1([C@@]2(C(O)=O)CCN(C[C@H]2C)[C@@H]2CC[C@@](CC2)(C#N)C=2C=CC(F)=CC=2)=CC=CC=C1 OICFWWJHIMKBCD-VALQNVSPSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 2
- 229960004853 betadex Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 229920002507 Poloxamer 124 Polymers 0.000 description 1
- 229920002516 Poloxamer 331 Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000593989 Scardinius erythrophthalmus Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000000218 acetic acid group Chemical class C(C)(=O)* 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000012928 buffer substance Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- QLBHNVFOQLIYTH-UHFFFAOYSA-L dipotassium;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical class [K+].[K+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O QLBHNVFOQLIYTH-UHFFFAOYSA-L 0.000 description 1
- 210000003717 douglas' pouch Anatomy 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 201000005111 ocular hyperemia Diseases 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229940093448 poloxamer 124 Drugs 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 238000012762 unpaired Student’s t-test Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
Definitions
- This invention relates to aqueous ophthalmic formulations for the treatment of ophthalmic allergic conditions.
- the invention relates to aqueous ophthalmic solutions for the treatment of ophthalmic allergic conditions wherein the active ingredient is levocabastine hydrochloride, whose chemical name is (-)-[3S-[l(cis),3 ⁇ ,4 ⁇ ]]-l-[4-cyano- 4-(4-fluorophenyl)-cyclohexyl]-3-methyl-4-phenyl-4-piperidinecarboxylic acid monohydrochloride, and whose molecular structure is the following:
- Levocabastine is disclosed and claimed in Stokbroekx et al., U.S. Patent No. 4,369,184.
- EP 0 149 197 A2 discloses pharmaceutical preparations of cyclodextrin complexes with various pharmaceutical products, including levocabastine.
- the characteristic signs and symptoms of ocular allergy include itching, swelling and red-eye and are induced by the local release of histamine.
- Levocabastine has been used to treat ophthalmic allergic conditions but only in the form of a suspension due to its limited solubility in aqueous media. The difficulties attendant to the use of suspensions in the treatment of ophthalmic conditions are well known. It is desirable, therefore, to provide a clear aqueous solution of levocabastine for the treatment of ophthalmic allergic conditions.
- Levocabastine is a new, potent, and specific anti-histamine agent with a specific binding capacity on the HI -receptor. It is used in the treatment of ophthalmic allergic conditions in the form of its hydrochloride salt. It is a very hydrophobic compound with limited solubility in water. For this reason, a suspension, instead of a solution, of levocabastine has been employed for the treatment of ophthalmic conditions such as allergic conjunctivitis. However, given the heterogeneous nature of a suspension, vigorous shaking of the container before use is required to achieve a consistent dose for administration. It has been found that patient compliance decreases when a suspension is administered because of the inconvenience associated with such formulations.
- suspensions are contraindicated for contact lens users, because of the particulate nature of the formulation. For these and others reasons, suspensions of levocabastine can not be universally employed in the treatment of ophthalmic allergic conditions.
- One object of the present invention is to provide an aqueous ophthalmic solution for the treatment of ophthalmic conditions.
- Another object of the present invention is to provide an aqueous ophthalmic solution for the treatment of ophthalmic conditions in which the active ingredient is levocabastine.
- a further object of the present invention is to provide a method of treating ophthalmic allergic conditions which comprises the topical administration of an aqueous solution containing levocabastine as the active ingredient.
- Another object of the present invention is an aqueous ophthalmic solution as defined in the main claim for the treatment of ocular allergic conditions.
- Another object of the present invention is the use of an aqueous ophthalmic solution as defined in the main claim in the preparation of a pharmaceutical composition for the treatment of ocular allergic conditions.
- the aqueous opthalmic solutions of the present invention are comprised of about 0.001 to about 2.0 % weight/volume of levocabastine, about 0.1 to about 20.0 % weight/volume of a solubilizing agent, about 0.001 to about 2.0 % weight/volume of a stabilizing agent, about 0.001 % to about 5.0 % weight/volume of a buffer, about 0.01 % to about 5.0 % weight/volume of a tonicity agent and sufficient water to adjust the formulation to 100 %.
- Suitable solubilizing agents are for example polysorbates such as polysorbate 20, polysorbate 60 or poly- sorbate 80; pluronics such as, for example, poloxamer 124, poloxamer 188, poloxa- mer 182 LF or poloxamer 331; or derivatives of cyclodextrin such as, for example, hydroxypiOpyl- ⁇ -cyclodextrin (HP- ⁇ -CD), ⁇ -cyclodextrin, ⁇ -cyclodextrin, ⁇ -cyclodextrin, dimethyl, hydroxypropyl, glucosyl, maltosyl and maltotriosyl derivatives of ⁇ -cyclo- dextrin as well as dimethyl, hydroxyethyl, hydroxypropyl, glucosyl, maltosyl and maltotriosyl derivatives of ⁇ -cyclodextrin.
- polysorbates such as polysorbate 20, polysorbate 60 or poly- sorbate 80
- the base may be employed as the free base or as the pharmaceutically acceptable acid addition salt.
- Such pharmaceutically acceptable salts are formed, for example, with strong inorganic acids, such as mineral acids, for example sulfuric acid, phosphoric acid or a hydrohalic acid, for example hydrochloric or hydrobromic acid.
- the preferred solubilizing agent is hydroxypropyl- ⁇ -cyclodextrin, in particular, hydroxypropyl- ⁇ -cyclodextrin having an MS (molar substitution - that is, number of substituents per glucose unit in the cyclodextrin molecule) of about 0.5.
- the solubilizing agent increases the solubility of levocabastine thus making the drug more bioavailable in the solution that it is in the known suspension formulations.
- the solubilizing agent is present in an amount of about 0.1 - 20.0 % weight/volume, preferably in an amount of about 0.5 - 15 % weight/volume and more preferably in an amount of about 1 - 10 % weight/volume.
- the stabilizing agent compounds such as the alkaline earth and the alkali metal salts of ethylenediaminetetraacetic acid (EDTA), edetate-disodium, edetate-dipotassium, sodium metabisulfite, ascorbic acid, acetyl crysteine, butylated hydroxyanisole, 2,6-di-tert- butyl-p-cresol and vitamin E may be employed.
- the purpose of the stabilizing agent is to prevent chemical degradation of the active ingredient.
- the stabilizing agent is present in an amount of about 0.001 - 2.0 % weight/volume, preferably in an amount of about 0.005 - 1.5 % weight/volume and more preferably in an amount of about 0.01 - 1.0 % weight/volume.
- the pH of the ophthalmic formulation must be maintained preferably between 4.0 and 8.0, more preferably between 5.0 and 8.0 and even more preferably between 6.0 and 8.0.
- buffers are added to the formulation.
- buffer substances are acetate, ascorbate, borate, hydrogen carbonate/carbonate, citrate, gluconate, lactate, sulfate, phosphate, propionate and TRIS (tromethamine) buffers.
- Tromethamine and borate buffer are preferred buffers.
- the amount of buffer substance added is, for example, from about 0.001 - 5.0 % weight/volume, preferably from about 0.01 - 4.0 % weight/volume and more preferably from about 0.1 - 3.0 % weight/volume.
- Tonicity agents are employed in the formulation in order to yield a final product which is physiologically isotonic.
- Suitable tonicity agents are, for example, ionic compounds, such as alkali metal or alkaline earth metal halides, such as, for example, CaCl 2 , KBr, KC1, LiCl, Nal, NaBr or NaCl, or boric acid.
- Non-ionic tonicity agents are, for example, urea, glycerol, sorbitol, mannitol, propylene glycol, or dextrose.
- Such a tonicity agents is present in amount of about 0.01 - 5.0 % weight/volume, preferably in an amount of about 0.05 - 2.0 % weight/volume and more preferably in an amount of about 0.1 - 1.0 % weight/volume.
- the preservative When employed in the formulation, the preservative will generally comprise from about 0.0001 to about 2.0 % and preferably from about 0.001 to about 1.0 % weight/volume of the formulation.
- a viscosity agent may be desirable to add to the formulation in order to prolong the residence time of the solution on the surface of the eye to gain an increased absorption and/or adsorption of the active ingredient, to decrease variability in dispensing the formulation and/or to otherwise improve the properties of the ophthalmic formulation.
- Suitable viscosity agents which can be employed in the formulation of the present invention include polyvinyl alcohol, polyvinylpyrrolidone, methylcellulose, hydroxy ⁇ propyl methylcellulose, hydroxyethyl cellulose, carboxymethylcellulose and hydroxy ⁇ propyl cellulose.
- the viscosity agent when employed, will comprise from about 0.01 to about 2.0 % and preferably from about 0.1 to about 1.0 % weight/volume of the formulation.
- the formulations of the present invention enhance the solubility of levocabstine and thus achieve a therapeutically active concentration of the drug in the aqueous solution. Moreover, the higher concentration of dissolved levocabastine in the solution of the present invention, when compared to that obtained in the suspension, provides greater availability of the drug for the treatment of the ophthalmic allergic condition. Thus, a higher level of the drug can be achieved in the eye in a relatively short time which results in rapid onset of the physiological effect.
- the compositions of the present invention are administered topically to the eye.
- the dosage range of the levocabastine administered is from about 0.0001 to about 5.0 mg per eye.
- the compositions can be administered directly or as solutions in a suitable ophthalmic vehicle. While the precise regimen to be employed is left to the discretion of the prescribing physician, it is generally recommended that the formulation be topically applied by placing one or two drops in each eye for about one to four times a day.
- Example 1 Levocabastine hydrochloride (269.82 mg) and hydroxyprOpyl- ⁇ -cyclodextrin (HP- ⁇ -CD) (37.507 g) are dissolved in distilled water (475 ml). Boric acid (5.015 g) sodium chloride (1.258 g) and EDTA-disodium (51.15 mg) are added and the pH is adjusted to 7.20 with 10 % sodium hydroxide. The final volume of the preparation is adjusted to 500 ml by the addition of distilled water to give the composition shown in Table 1.
- Example 2 Levocabastine hydrochloride (81.52 mg) and HP- ⁇ -CD (12.5 g) are dissolved in distilled water (230 ml). Boric acid (2.5 g) sodium chloride (0.7 g) and EDTA disodium (25 mg) are added and the pH is adjusted to 7.11 with 10 % sodium hydroxide. The final volume of the preparation is adjusted to 250 ml by the addition of distilled water to give the composition shown in Table 2. Table 2
- Example 3 LevocabastincHCl (27.25 g) and HP- ⁇ -CD) (8.75 g) are dissolved in distilled water (230 ml). Boric acid (2.5 g), sodium chloride (0.75 g) and EDTA-disodium (25 mg) are added and pH is adjusted to 7.2 with 10 % sodium hydroxide. The final volume of the preparation is adjusted to 250 ml by distilled water to give the composition shown in Table 3.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Levocabastine hydrochloride, (-)-[3S-[1(cis),3α,4β]]-1-[4-cyano-4-(4-fluorophenyl)-cyclohexyl]-3-methyl-4-phenyl-4-piperidinecarboxylic acid monohydrochloride, a potent hydrophobic antihistamine, has been prepared as a homogeneous aqueous solution containing hydroxypropyl-β-cyclodextrin as the solubilizing agent. The solution is useful in the treatment of allergic conjunctivitis.
Description
Aqueous solution of levocabastine for ophthalmic use
This invention relates to aqueous ophthalmic formulations for the treatment of ophthalmic allergic conditions. In particular, the invention relates to aqueous ophthalmic solutions for the treatment of ophthalmic allergic conditions wherein the active ingredient is levocabastine hydrochloride, whose chemical name is (-)-[3S-[l(cis),3α,4β]]-l-[4-cyano- 4-(4-fluorophenyl)-cyclohexyl]-3-methyl-4-phenyl-4-piperidinecarboxylic acid monohydrochloride, and whose molecular structure is the following:
Levocabastine is disclosed and claimed in Stokbroekx et al., U.S. Patent No. 4,369,184. EP 0 149 197 A2 discloses pharmaceutical preparations of cyclodextrin complexes with various pharmaceutical products, including levocabastine.
The characteristic signs and symptoms of ocular allergy include itching, swelling and red-eye and are induced by the local release of histamine. Levocabastine has been used to treat ophthalmic allergic conditions but only in the form of a suspension due to its limited solubility in aqueous media. The difficulties attendant to the use of suspensions in the treatment of ophthalmic conditions are well known. It is desirable, therefore, to provide a clear aqueous solution of levocabastine for the treatment of ophthalmic allergic conditions.
Levocabastine is a new, potent, and specific anti-histamine agent with a specific binding capacity on the HI -receptor. It is used in the treatment of ophthalmic allergic conditions in the form of its hydrochloride salt. It is a very hydrophobic compound with limited solubility in water. For this reason, a suspension, instead of a solution, of levocabastine has been employed for the treatment of ophthalmic conditions such as allergic conjunctivitis. However, given the heterogeneous nature of a suspension, vigorous shaking of the container before use is required to achieve a consistent dose for administration. It
has been found that patient compliance decreases when a suspension is administered because of the inconvenience associated with such formulations. In contrast, a solution provides a homogeneous and consistent dosage with each application, which leads to better patient compliance. Moreover, suspensions are contraindicated for contact lens users, because of the particulate nature of the formulation. For these and others reasons, suspensions of levocabastine can not be universally employed in the treatment of ophthalmic allergic conditions.
One object of the present invention is to provide an aqueous ophthalmic solution for the treatment of ophthalmic conditions.
Another object of the present invention is to provide an aqueous ophthalmic solution for the treatment of ophthalmic conditions in which the active ingredient is levocabastine.
A further object of the present invention is to provide a method of treating ophthalmic allergic conditions which comprises the topical administration of an aqueous solution containing levocabastine as the active ingredient.
Another object of the present invention is an aqueous ophthalmic solution as defined in the main claim for the treatment of ocular allergic conditions.
Another object of the present invention is the use of an aqueous ophthalmic solution as defined in the main claim in the preparation of a pharmaceutical composition for the treatment of ocular allergic conditions.
The aqueous opthalmic solutions of the present invention are comprised of about 0.001 to about 2.0 % weight/volume of levocabastine, about 0.1 to about 20.0 % weight/volume of a solubilizing agent, about 0.001 to about 2.0 % weight/volume of a stabilizing agent, about 0.001 % to about 5.0 % weight/volume of a buffer, about 0.01 % to about 5.0 % weight/volume of a tonicity agent and sufficient water to adjust the formulation to 100 %.
As the solubilizing agent any suitable surfactant may be employed. Suitable solubilizing agents are for example polysorbates such as polysorbate 20, polysorbate 60 or poly- sorbate 80; pluronics such as, for example, poloxamer 124, poloxamer 188, poloxa- mer 182 LF or poloxamer 331; or derivatives of cyclodextrin such as, for example, hydroxypiOpyl-β-cyclodextrin (HP-β-CD), α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin,
dimethyl, hydroxypropyl, glucosyl, maltosyl and maltotriosyl derivatives of β-cyclo- dextrin as well as dimethyl, hydroxyethyl, hydroxypropyl, glucosyl, maltosyl and maltotriosyl derivatives of α-cyclodextrin. In those cases where the solubilizing agent is a base, the base may be employed as the free base or as the pharmaceutically acceptable acid addition salt. Such pharmaceutically acceptable salts are formed, for example, with strong inorganic acids, such as mineral acids, for example sulfuric acid, phosphoric acid or a hydrohalic acid, for example hydrochloric or hydrobromic acid. The preferred solubilizing agent is hydroxypropyl-β-cyclodextrin, in particular, hydroxypropyl- β-cyclodextrin having an MS (molar substitution - that is, number of substituents per glucose unit in the cyclodextrin molecule) of about 0.5. The solubilizing agent increases the solubility of levocabastine thus making the drug more bioavailable in the solution that it is in the known suspension formulations. The solubilizing agent is present in an amount of about 0.1 - 20.0 % weight/volume, preferably in an amount of about 0.5 - 15 % weight/volume and more preferably in an amount of about 1 - 10 % weight/volume.
As the stabilizing agent compounds such as the alkaline earth and the alkali metal salts of ethylenediaminetetraacetic acid (EDTA), edetate-disodium, edetate-dipotassium, sodium metabisulfite, ascorbic acid, acetyl crysteine, butylated hydroxyanisole, 2,6-di-tert- butyl-p-cresol and vitamin E may be employed. The purpose of the stabilizing agent is to prevent chemical degradation of the active ingredient. The stabilizing agent is present in an amount of about 0.001 - 2.0 % weight/volume, preferably in an amount of about 0.005 - 1.5 % weight/volume and more preferably in an amount of about 0.01 - 1.0 % weight/volume.
The pH of the ophthalmic formulation must be maintained preferably between 4.0 and 8.0, more preferably between 5.0 and 8.0 and even more preferably between 6.0 and 8.0. For this reason buffers are added to the formulation. Examples of buffer substances are acetate, ascorbate, borate, hydrogen carbonate/carbonate, citrate, gluconate, lactate, sulfate, phosphate, propionate and TRIS (tromethamine) buffers. Tromethamine and borate buffer are preferred buffers. The amount of buffer substance added is, for example, from about 0.001 - 5.0 % weight/volume, preferably from about 0.01 - 4.0 % weight/volume and more preferably from about 0.1 - 3.0 % weight/volume.
Tonicity agents are employed in the formulation in order to yield a final product which is physiologically isotonic. Suitable tonicity agents are, for example, ionic compounds, such as alkali metal or alkaline earth metal halides, such as, for example, CaCl2, KBr, KC1,
LiCl, Nal, NaBr or NaCl, or boric acid. Non-ionic tonicity agents are, for example, urea, glycerol, sorbitol, mannitol, propylene glycol, or dextrose. Such a tonicity agents is present in amount of about 0.01 - 5.0 % weight/volume, preferably in an amount of about 0.05 - 2.0 % weight/volume and more preferably in an amount of about 0.1 - 1.0 % weight/volume.
When the formulation of the present invention is packaged in a unit-dose container, the risk of microbial contamination is small and, therefore, the use of a preservative is not required. Ophthalmic products, however, are typically packaged in multiple-dose containers. Preservatives are often employed in multiple dose containers to prevent microbial contamination of the formulation during use or storage after use. Examples of preservatives which can be employed in the formulation of the present invention include benzalkonium chloride, thiomersal, chlorobutanol, methyl paraben, propyl paraben, phenylethyl alcohol, sorbic acid and sepazonium chloride. When employed as an ingredient in the formulation, the preservative will generally comprise from about 0.0001 to about 2.0 % and preferably from about 0.001 to about 1.0 % weight/volume of the formulation.
It may be desirable to add a viscosity agent to the formulation in order to prolong the residence time of the solution on the surface of the eye to gain an increased absorption and/or adsorption of the active ingredient, to decrease variability in dispensing the formulation and/or to otherwise improve the properties of the ophthalmic formulation. Suitable viscosity agents which can be employed in the formulation of the present invention include polyvinyl alcohol, polyvinylpyrrolidone, methylcellulose, hydroxy¬ propyl methylcellulose, hydroxyethyl cellulose, carboxymethylcellulose and hydroxy¬ propyl cellulose. Generally, the viscosity agent, when employed, will comprise from about 0.01 to about 2.0 % and preferably from about 0.1 to about 1.0 % weight/volume of the formulation.
The formulations of the present invention enhance the solubility of levocabstine and thus achieve a therapeutically active concentration of the drug in the aqueous solution. Moreover, the higher concentration of dissolved levocabastine in the solution of the present invention, when compared to that obtained in the suspension, provides greater availability of the drug for the treatment of the ophthalmic allergic condition. Thus, a higher level of the drug can be achieved in the eye in a relatively short time which results in rapid onset of the physiological effect.
The compositions of the present invention are administered topically to the eye. The dosage range of the levocabastine administered is from about 0.0001 to about 5.0 mg per eye. The compositions can be administered directly or as solutions in a suitable ophthalmic vehicle. While the precise regimen to be employed is left to the discretion of the prescribing physician, it is generally recommended that the formulation be topically applied by placing one or two drops in each eye for about one to four times a day.
The following examples are used to illustrate the present invention but are not intended to limit the scope of the invention.
Example 1: Levocabastine hydrochloride (269.82 mg) and hydroxyprOpyl-β-cyclodextrin (HP-β-CD) (37.507 g) are dissolved in distilled water (475 ml). Boric acid (5.015 g) sodium chloride (1.258 g) and EDTA-disodium (51.15 mg) are added and the pH is adjusted to 7.20 with 10 % sodium hydroxide. The final volume of the preparation is adjusted to 500 ml by the addition of distilled water to give the composition shown in Table 1.
Table 1
Composition of 0.05 % aqueous levocabastine solution
Levocabastine.HCl 0.054 %
HP-β-CD 7.5 %
Boric acid 1.0 %
NaCl 0.25 %
Edetate-disodium 0.01 %
Water q.s. 100 %
Example 2: Levocabastine hydrochloride (81.52 mg) and HP-β-CD (12.5 g) are dissolved in distilled water (230 ml). Boric acid (2.5 g) sodium chloride (0.7 g) and EDTA disodium (25 mg) are added and the pH is adjusted to 7.11 with 10 % sodium hydroxide. The final volume of the preparation is adjusted to 250 ml by the addition of distilled water to give the composition shown in Table 2.
Table 2
Composition of 0.03 % aqueous levocabastine solution
Levocabastine-HCl 0.033 %
HP-β-CD 5.0 %
Boric acid 1.0 %
NaCl 0.28 %
Edetate-disodium 0.01 %
Water q.s. 100 %
Example 3: LevocabastincHCl (27.25 g) and HP-β-CD) (8.75 g) are dissolved in distilled water (230 ml). Boric acid (2.5 g), sodium chloride (0.75 g) and EDTA-disodium (25 mg) are added and pH is adjusted to 7.2 with 10 % sodium hydroxide. The final volume of the preparation is adjusted to 250 ml by distilled water to give the composition shown in Table 3.
Table 3
Composition of 0.01 % aqueous levocabastine solution
Levocabastine-HCl 0.0109 %
HP-β-CD 3.5 %
Boric acid 1.0 %
NaCl 0.30 %
Edetate-disodium 0.01 %
Water q.s. 100 %
Example 4: Bioavailability Study
Method: Two trops of an 0.05 % aqueous levocabastine suspension and two trops of an 0.05 % aqueous levocabastine solution are applied to the lower cul de sac of NZW rabbits (2.5-3 kg body weight). At various time points rabbits are sacrificed (n=5/time point) and the aqueous humor and the blood are collected. Plasma is fractionated by centrifugation. The concentration of levocabastine in these biological fluids is measured using a radio- immuno assay. The area under the concentration-time curve (AUC) between 0 and 24 hours is determined by the trapezoidal rule. The maximum concentration (Cmax) and the time needed to reach the Cmax (Tmax) are estimated by visual approximation.
Results
Table 4. Pharmacokinetic parameters from the aqueous humor and plasma concentration- time profiles obtained after the topical administration of a single dose of levocabastine solution and a levocabastine suspension.
Formulation Cmax Tmax AUCQ-24 (ng ml) (hr) (hr-ng/ml)
Aqueous Humor
Solution 53.48* 0.5 96.13*
Suspension 20.44* 0.5 - 1 65.35*
Plasma
Solution 4.81* 2 38.84*
Suspension 1.61* 3 - 4 26.32*
: Significant difference (P > 0.05) between solution and suspension applications using the unpaired Student's t test
From the results, it is noted that the bioavailability and Cmax in the aqueous humor and plasma are increased by 1.5-2 times with administration of the solution over the administration of the suspension. In addition, the time needed to reach the Cmax is shorter for the solution.
Example 5: Pharmacological Efficacy study
Method: Two drops each of aqueous levocabastine solutions, at 0.01 %, 0.03 % and 0.05 %, two drops of an aqueous levocabastine suspension at 0.05 % are administered to one eye of NEW rabbits (n=8/treatment). The contralateral eye is treated with the corresponding placebo. One drop of histamine solution (25 mg/ml) is applied to each eye at 15 minutes after the drug/placebo dosing to induce the allergic reactions. Palpebral and bulbar chemosis are evaluated using a scale from 0 to 3 according to the severity of the response at the various time points after the histamine challenge. The difference beween the score obtained from drug treatment and placebo treatment is obtained by subtracting the score of the drug treatment from that of each corresponding placebo treatment.
The summarized results indicate that the 0.01 %, 0.03 %, and 0.05 % levocabastine
solution and the 0.05 % levocabastine suspension effectively inhibit bulbar and palpebral chemosis after the histamine challenge.
The results further demonstrate that the levocabastine solutions and the levocabastine suspension effectively inhibit bulbar and palpebral chemosis within about 3 to 5 minutes after the histamine challenge. The maximum inhibiting effect for both the solutions and the suspension is obtained after about 20 to 40 minutes.
Claims
1. An aqueous ophthalmic solution comprising 0.001 - 2.0 weight % of levocabastine, 0.1 - 20.0 weight % of a solubilizing agent, 0.001 - 2.0 weight % of a stabilizing agent, 0.001 - 5 weight % of a buffer, 0.01 - 5.0 weight % of a tonicity agent and water to adjust the formulation to 100 %.
2. An aqueous ophthalmic solution according to claim 1, wherein the solubilizing agent is present in an amount of about 0.5 - 15 weight %.
3. The aqueous ophthalmic solution of claim 1 wherein the solubilizing agent is selected from polysorbate, pluronic, and derivatives of cyclodextrins.
4. The aqueous ophthalmic solution of claim 1 wherein the stabilizing agent is selected from edetate disodium, sodium metabisulfite, ascorbic acid, acetyl cysteine, butylated hydroxyanisole, 2,6-di-tert-butyl-p-cresol, vitamin E and cyclodextrins.
5. An aqueous ophthalmic solution according to claim 1, wherein the stabilizing agent is present in an amount of about 0.005 - 1.5 weight %.
6. The aqueous ophthalmic solution of claim 1 wherein the buffer is selected from alkali metal acetates, monobasic phosphates, dibasic phosphates, borates, citrates, sulfates and boric acid.
7. An aqueous ophthalmic solution according to claim 1, wherein the buffer is present in an amount of about 0.01 - 4.0 weight %.
8. The aqueous ophthalmic solution of claim 1 wherein the tonicity agent is selected from ionic compounds, such as alkali metal or alkaline earth metal halides, such as, for example, CaCl2, KBr, KCl, LiCl, Nal, NaBr or NaCl, or boric acid; or wherein the tonicity agent is selected from non-ionic tonicity agents such as urea, glycerol, sorbitol, mannitol, propylene glycol, or dextrose.
9. The aqueous ophthalmic solution of claim 1 which comprises about 0.05 % of levocabastine, 7.5 % of hydroxypropyl-β-cyclodextrin, 0.01 % edetate disodium, 1.0 % boric acid and 0.25 % sodium chloride.
10. The aqueous ophthalmic solution of claim 1 which comprises about 0.03 % of levocabastine, 7.5 % of hydroxypropyl-β-cyclodextrin, 0.01 % edetate disodium, 1.0 % boric acid and 0.28 % sodium chloride.
11. The aqueous ophthalmic solution of claim 1 which comprises about 0.01 % of levocabastine, 3.5 % of hydroxypropyl-β-cyclodextrin, 0.01 % edetate disodium, 1.0 % boric acid and 0.3 % sodium chloride.
12. The aqueous ophthalmic solution of claim 1 wherein the pH is between 4.0 and 8.0.
13. The aqueous ophthalmic solution of claim 1, 9, 10 and 11 wherein a preservative is additionally present.
14. The aqueous ophthalmic solution of claim 13 wherein the preservative is selected from the group consisting of benzalkonium chloride, thiomersal, chlorobutanol, methylparaben, propyl- paraben, phenylethyl alcohol, sorbic acid and sepazonium chloride.
15. The aqueous ophthalmic solution of claim 14 wherein the preservative comprises 0.0001 to 2.0 weight % of the formulation.
16. The aqueous ophthalmic solution of claim 1, 9, 10 and 11 wherein a viscosity agent is additionally present.
17. The aqueous ophthalmic solution of claim 16 wherein the viscosity agent is selected from poly- vinyl alcohol, polyvinylpyrrolidone methylcellulose, hydroxypropylmethylcellulose, hydroxyethyl- cellulose, carboxymethylcellulose and hydroxypropylcellulose.
18. The aqueous ophthalmic solution of claim 17 wherein the viscosity agent comprises 0.01 to 2.0 weight % of the formulation.
19. A method of treating ocular allergic conditions which comprises administering topically to the affected eye an effective amount of an aqueous ophthalmic solution as defined in claim 1.
20. A method of treating allergic conjunctivitis which comprises administering topically to the affected eye an effective amount of an aqueous ophthalmic solution as defined in claim 1. PCMB95/00143 WO 95/25518
- 11 -
21. Aqueous ophthalmic solution as defined in claim 1 for the treatment of ocular allergic conditions.
22. Use of an aqueous ophthalmic solution as defined in claim 1 in the preparation of a pharmaceutical composition for the treatment of ocular allergic conditions.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU17169/95A AU1716995A (en) | 1994-03-18 | 1995-03-08 | Aqueous solution of levocabastine for ophthalmic use |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21452394A | 1994-03-18 | 1994-03-18 | |
| US08/214,523 | 1994-03-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1995025518A1 true WO1995025518A1 (en) | 1995-09-28 |
Family
ID=22799401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB1995/000143 WO1995025518A1 (en) | 1994-03-18 | 1995-03-08 | Aqueous solution of levocabastine for ophthalmic use |
Country Status (4)
| Country | Link |
|---|---|
| AU (1) | AU1716995A (en) |
| IL (1) | IL112947A0 (en) |
| WO (1) | WO1995025518A1 (en) |
| ZA (1) | ZA952203B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006137433A1 (en) * | 2005-06-21 | 2006-12-28 | Wakamoto Pharmaceutical Co., Ltd. | Aqueous preparation having levocabastine solubilized therein |
| RU2495661C2 (en) * | 2007-03-30 | 2013-10-20 | Сифи С.П.А. | Pharmaceutical formulations of non-polar and polar lipids for ophthalmological application |
| US9474746B2 (en) | 2006-03-17 | 2016-10-25 | Johnson & Johnson Vision Care, Inc. | Methods for stabilizing oxidatively unstable compositions |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0034415A1 (en) * | 1980-01-24 | 1981-08-26 | Janssen Pharmaceutica N.V. | 1-(Cyclohexyl or cyclohexenyl)-4-aryl-4-piperidinecarboxylic acid derivatives |
| EP0149197A2 (en) * | 1983-12-21 | 1985-07-24 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are sparingly soluble in water or instable and methods for their preparation |
| WO1992005783A1 (en) * | 1990-09-28 | 1992-04-16 | Merck & Co., Inc. | Ibuprofen-antihistamine combinations |
| US5192780A (en) * | 1989-12-18 | 1993-03-09 | Alcon Laboratories, Inc. | Methods using antiallergics and antihistamines |
| WO1994008551A2 (en) * | 1992-10-09 | 1994-04-28 | The Procter & Gamble Company | Pharmaceutical compositions and methods for treating cold symptoms |
-
1995
- 1995-03-08 AU AU17169/95A patent/AU1716995A/en not_active Abandoned
- 1995-03-08 WO PCT/IB1995/000143 patent/WO1995025518A1/en active Application Filing
- 1995-03-09 IL IL11294795A patent/IL112947A0/en unknown
- 1995-03-17 ZA ZA952203A patent/ZA952203B/en unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0034415A1 (en) * | 1980-01-24 | 1981-08-26 | Janssen Pharmaceutica N.V. | 1-(Cyclohexyl or cyclohexenyl)-4-aryl-4-piperidinecarboxylic acid derivatives |
| EP0149197A2 (en) * | 1983-12-21 | 1985-07-24 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are sparingly soluble in water or instable and methods for their preparation |
| US5192780A (en) * | 1989-12-18 | 1993-03-09 | Alcon Laboratories, Inc. | Methods using antiallergics and antihistamines |
| WO1992005783A1 (en) * | 1990-09-28 | 1992-04-16 | Merck & Co., Inc. | Ibuprofen-antihistamine combinations |
| WO1994008551A2 (en) * | 1992-10-09 | 1994-04-28 | The Procter & Gamble Company | Pharmaceutical compositions and methods for treating cold symptoms |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006137433A1 (en) * | 2005-06-21 | 2006-12-28 | Wakamoto Pharmaceutical Co., Ltd. | Aqueous preparation having levocabastine solubilized therein |
| JPWO2006137433A1 (en) * | 2005-06-21 | 2009-01-22 | わかもと製薬株式会社 | Aqueous drug with solubilized levocabastine |
| US9474746B2 (en) | 2006-03-17 | 2016-10-25 | Johnson & Johnson Vision Care, Inc. | Methods for stabilizing oxidatively unstable compositions |
| RU2495661C2 (en) * | 2007-03-30 | 2013-10-20 | Сифи С.П.А. | Pharmaceutical formulations of non-polar and polar lipids for ophthalmological application |
Also Published As
| Publication number | Publication date |
|---|---|
| IL112947A0 (en) | 1995-06-29 |
| ZA952203B (en) | 1995-09-18 |
| AU1716995A (en) | 1995-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8969385B2 (en) | Ocular formulations of norketotifen | |
| JP5656692B2 (en) | Formulation containing amiodarone and sulfoalkyl ether cyclodextrin | |
| EP2709610B1 (en) | High concentration olopatadine ophthalmic composition | |
| TWI324925B (en) | Ophthalmic composition | |
| WO2002100437A2 (en) | Ophthalmic compositions comprising hyaluronic acid | |
| US5631297A (en) | Anandamides useful for the treatment of intraocular hypertension, ophthalmic compositions containing the same and methods of use of the same | |
| EP2123278A1 (en) | Eye drop reparation comprising latanoprost | |
| EP0774254A1 (en) | Pharmaceutical composition for preventing or treating dry eye or disease caused thereby comprising 12-sulfodehydroabietic acid | |
| WO2011138801A1 (en) | Novel ophthalmic compositions | |
| US8034371B2 (en) | Intranasal compositions | |
| WO1995025518A1 (en) | Aqueous solution of levocabastine for ophthalmic use | |
| EP0695545B1 (en) | Use of diphenylethane derivatives for the manufacture of a medicament for the treatment of glaucoma | |
| US20210299121A1 (en) | Cetirizine ophthalmic compositions | |
| US20100130444A1 (en) | Complexes of prostaglandin derivatives and monosubstituted, charged beta-cyclodextrins | |
| WO1999022715A1 (en) | Sustained release eyedrops | |
| WO2008015695A2 (en) | Inclusion complex of olopatadine and cyclodextrin | |
| EP1004309A1 (en) | Israpafant-containing water-base preparations | |
| US5733938A (en) | Combination of levobunolol and dipivefrin for topical ophthalmic use | |
| WO2002100436A2 (en) | Ophthalmic once-a-day composition | |
| JPH02262518A (en) | Intraocular pressure-adjusting agent | |
| KR20040066825A (en) | Use of an Ascomycin for the Treatment of Blepharitis | |
| HK1027764B (en) | Ophthalmic compositions for soft contact lens comprising terpenoid | |
| HK1027764A1 (en) | Ophthalmic compositions for soft contact lens comprising terpenoid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU JP KG KP KR KZ LK LR LT LV MD MG MN MX NO NZ PL RO RU SG SI SK TJ TT UA US UZ VN |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: CA |